Carlos Arteaga
Carlos L. Arteaga, M.D., was appointed Director of the Harold C. Simmons Comprehensive Cancer Center and Associate Dean of Oncology Programs at UT Southwestern Medical Center in Dallas in September 2017. Previously, he was the Associate Director for Clinical Research, director of the Center for Cancer Targeted Therapies, and professor of Cancer Biology and Medicine at Vanderbilt-Ingram Cancer Center. In 2014–2015, he was the president of the American Association for Cancer Research.Arteaga earned his medical degree from the Universidad de Guayaquil in Ecuador in 1980, where his father was the dean of medicine. He came to the United States intending to specialize in cardiology after his internal medicine residency at Emory University, but changed course and instead did a fellowship in hematology-oncology at University of Texas Health Science Center.
Arteaga joined the faculty at Vanderbilt in 1989 and since 2002, has directed the NCI-funded Vanderbilt Breast Cancer Specialized Program of Research Excellence (SPORE). Provided by Wikipedia
Showing 1 - 13 results of 13 for search 'Carlos L. Arteaga', query time: 0.04s
Refine Results
-
1
Abrogating endocrine resistance by targeting ER alpha and PI3K in breast cancer by Emily M Fox, Carlos L Arteaga, Todd W Miller
Published 2012-10-01
Article -
2
-
3
-
4
Linking changes in epithelial morphogenesis to cancer mutations using computational modeling. by Katarzyna A Rejniak, Shizhen E Wang, Nicole S Bryce, Hang Chang, Bahram Parvin, Jerome Jourquin, Lourdes Estrada, Joe W Gray, Carlos L Arteaga, Alissa M Weaver, Vito Quaranta, Alexander R A Anderson
Published 2010-08-01
Article -
5
Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment by Shuying Liu, Shelly M. Xie, Wenbin Liu, Mihai Gagea, Ariella B. Hanker, Nguyen Nguyen, Akshara Singareeka Raghavendra, Gloria Yang-Kolodji, Fuliang Chu, Sattva S. Neelapu, Adriano Marchese, Samir Hanash, Johann Zimmermann, Carlos L. Arteaga, Debasish Tripathy
Published 2023-06-01
Article -
6
Combined Dusp4 and p53 loss with Dbf4 amplification drives tumorigenesis via cell cycle restriction and replication stress escape in breast cancer by Ann Hanna, Mellissa J. Nixon, M. Valeria Estrada, Violeta Sanchez, Quanhu Sheng, Susan R. Opalenik, Abigail L. Toren, Joshua Bauer, Phillip Owens, Frank M. Mason, Rebecca S. Cook, Melinda E. Sanders, Carlos L. Arteaga, Justin M. Balko
Published 2022-07-01
Article -
7
Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer by Kyung-min Lee, Angel L. Guerrero-Zotano, Alberto Servetto, Dhivya R. Sudhan, Chang-Ching Lin, Luigi Formisano, Valerie M. Jansen, Paula González-Ericsson, Melinda E. Sanders, Thomas P. Stricker, Ganesh Raj, Kevin M. Dean, Reto Fiolka, Lewis C. Cantley, Ariella B. Hanker, Carlos L. Arteaga
Published 2020-10-01
Article -
8
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer by Ana C. Garrido-Castro, Cristina Saura, Romualdo Barroso-Sousa, Hao Guo, Eva Ciruelos, Begoña Bermejo, Joaquin Gavilá, Violeta Serra, Aleix Prat, Laia Paré, Pamela Céliz, Patricia Villagrasa, Yisheng Li, Jennifer Savoie, Zhan Xu, Carlos L. Arteaga, Ian E. Krop, David B. Solit, Gordon B. Mills, Lewis C. Cantley, Eric P. Winer, Nancy U. Lin, Jordi Rodon
Published 2020-11-01
Article -
9
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer by Chang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, Lei Guo, Yunpeng Gao, Emmanuel Bikorimana, Andrew Lemoff, Yisheng V. Fang, He Zhang, Yanfeng Zhang, Dan Ye, Isabel Soria-Bretones, Alberto Servetto, Kyung-min Lee, Xuemei Luo, Joseph J. Otto, Hiroaki Akamatsu, Fabiana Napolitano, Ram Mani, David W. Cescon, Lin Xu, Yang Xie, Joshua T. Mendell, Ariella B. Hanker, Carlos L. Arteaga
Published 2024-03-01
Article -
10
A versatile oblique plane microscope for large-scale and high-resolution imaging of subcellular dynamics by Etai Sapoznik, Bo-Jui Chang, Jaewon Huh, Robert J Ju, Evgenia V Azarova, Theresa Pohlkamp, Erik S Welf, David Broadbent, Alexandre F Carisey, Samantha J Stehbens, Kyung-Min Lee, Arnaldo Marín, Ariella B Hanker, Jens C Schmidt, Carlos L Arteaga, Bin Yang, Yoshihiko Kobayashi, Purushothama Rao Tata, Rory Kruithoff, Konstantin Doubrovinski, Douglas P Shepherd, Alfred Millett-Sikking, Andrew G York, Kevin M Dean, Reto P Fiolka
Published 2020-11-01
Article -
11
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer by Luigi Formisano, Yao Lu, Alberto Servetto, Ariella B. Hanker, Valerie M. Jansen, Joshua A. Bauer, Dhivya R. Sudhan, Angel L. Guerrero-Zotano, Sarah Croessmann, Yan Guo, Paula Gonzalez Ericsson, Kyung-min Lee, Mellissa J. Nixon, Luis J. Schwarz, Melinda E. Sanders, Teresa C. Dugger, Marcelo Rocha Cruz, Amir Behdad, Massimo Cristofanilli, Aditya Bardia, Joyce O’Shaughnessy, Rebecca J. Nagy, Richard B. Lanman, Nadia Solovieff, Wei He, Michelle Miller, Fei Su, Yu Shyr, Ingrid A. Mayer, Justin M. Balko, Carlos L. Arteaga
Published 2019-03-01
Article -
12
Correction: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer by James D Joseph, Beatrice Darimont, Wei Zhou, Alfonso Arrazate, Amy Young, Ellen Ingalla, Kimberly Walter, Robert A Blake, Jim Nonomiya, Zhengyu Guan, Lorna Kategaya, Steven P Govek, Andiliy G Lai, Mehmet Kahraman, Dan Brigham, John Sensintaffar, Nhin Lu, Gang Shao, Jing Qian, Kate Grillot, Michael Moon, Rene Prudente, Eric Bischoff, Kyoung-Jin Lee, Celine Bonnefous, Karensa L Douglas, Jackaline D Julien, Johnny Y Nagasawa, Anna Aparicio, Josh Kaufman, Benjamin Haley, Jennifer M Giltnane, Ingrid E Wertz, Mark R Lackner, Michelle A Nannini, Deepak Sampath, Luis Schwarz, Henry Charles Manning, Mohammed Noor Tantawy, Carlos L Arteaga, Richard A Heyman, Peter J Rix, Lori Friedman, Nicholas D Smith, Ciara Metcalfe, Jeffrey H Hager
Published 2019-01-01
Article -
13
The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer by James D Joseph, Beatrice Darimont, Wei Zhou, Alfonso Arrazate, Amy Young, Ellen Ingalla, Kimberly Walter, Robert A Blake, Jim Nonomiya, Zhengyu Guan, Lorna Kategaya, Steven P Govek, Andiliy G Lai, Mehmet Kahraman, Dan Brigham, John Sensintaffar, Nhin Lu, Gang Shao, Jing Qian, Kate Grillot, Michael Moon, Rene Prudente, Eric Bischoff, Kyoung-Jin Lee, Celine Bonnefous, Karensa L Douglas, Jackaline D Julien, Johnny Y Nagasawa, Anna Aparicio, Josh Kaufman, Benjamin Haley, Jennifer M Giltnane, Ingrid E Wertz, Mark R Lackner, Michelle A Nannini, Deepak Sampath, Luis Schwarz, Henry Charles Manning, Mohammed Noor Tantawy, Carlos L Arteaga, Richard A Heyman, Peter J Rix, Lori Friedman, Nicholas D Smith, Ciara Metcalfe, Jeffrey H Hager
Published 2016-07-01
Article